Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tacrolimus Treatment for Refractory Autoimmune Cytopenia

NCT03918265 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT03918265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03918265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tacrolimus Treatment for Refractory Autoimmune Cytopenia
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
May 4, 2019
Completion date
November 10, 2021
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hemolytic anemia, evans syndrome, pure red cell aplasia